Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2000
03/21/2000CA2146097C 1h-indole-3-glyoxylamide spla2 inhibitors
03/21/2000CA2062976C Use of sebacic acid and derivatives thereof in enteral and parenteral nutrition and pharmaceutical compositions containing said compounds
03/21/2000CA2027773C Treatment of shock by cyclodextrins and their derivatives
03/17/2000CA2282112A1 Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
03/16/2000WO2000014236A2 Grf analogs with increased biological potency
03/16/2000WO2000014095A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
03/16/2000WO2000014090A1 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine derivatives
03/16/2000WO2000014086A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000WO2000014067A1 Piperidine derivatives
03/16/2000WO2000014054A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000WO2000013706A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000WO2000013696A1 Composition for improving mental capabilities in mammals
03/16/2000WO2000013667A1 Lipstatin derivative-soluble fiber tablets
03/16/2000WO2000013650A2 Neuroprotection
03/16/2000WO2000002881A3 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein
03/16/2000WO1999064598A3 Novel insulin analogs with enhanced zinc binding
03/16/2000WO1999062939A3 Glycoproteins having lipid mobilising properties and therapeutic applications thereof
03/16/2000WO1999061471A3 Human transmembrane proteins
03/16/2000WO1999050403A9 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
03/16/2000DE19841930A1 Stabile, pulverförmige Lycopin-Formulierungen, enthaltend Lycopin mit einem Kristallinitätsgrad von größer 20% Sturdy, powder-like lycopene formulations comprising lycopene having a degree of crystallinity of greater than 20%
03/16/2000CA2343214A1 Neuroprotection
03/16/2000CA2343168A1 Piperidine derivatives
03/16/2000CA2343027A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
03/16/2000CA2342898A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000CA2342882A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2342625A1 Lipstatin derivative-soluble fiber tablets
03/16/2000CA2342280A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000CA2342070A1 Grf analogs with increased biological potency
03/16/2000CA2306165A1 Composition for improving mental capabilities in mammals
03/15/2000EP0985411A1 Sterol esters in tableted solid dosage forms
03/15/2000EP0985149A1 Methods for evaluating tissue morphogenesis and activity
03/15/2000EP0985040A1 Preparation of glycosylated tumor necrosis factor
03/15/2000EP0985038A1 Sodium channel receptor
03/15/2000EP0984986A2 Human type 3 ryanodine receptor protein and dna molecules coding therefor
03/15/2000EP0984965A1 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
03/15/2000EP0984960A1 N-triazolyl-2-indolecarboxamides and their use as cck-a agonists
03/15/2000EP0984952A1 A new salt
03/15/2000EP0984934A1 Novel orally active iron (iii) chelators
03/15/2000EP0984930A1 2-indolinone derivatives as modulators of protein kinase activity
03/15/2000EP0984780A1 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
03/15/2000EP0984779A1 Somatostatin agonists
03/15/2000EP0984778A1 Neuropeptide-y ligands
03/15/2000EP0984699A1 Method of inhibiting immune system destruction of transplanted viable cells
03/15/2000EP0619805B1 5-(hetero- or carbocyclylamino)-indole derivatives, their preparation and their use as 5-ht1 agonists
03/15/2000CN1247537A Sulfonamide compounds having 5-HT receptor activity
03/15/2000CN1247470A Method of using cycloxygenase-2 inhibitors as anti-angiogenic agents
03/15/2000CN1247227A Synergistic technique of ordinary beer and fruit wine for nourishing vital essence, invigorating vital function and reducing blood pressure and fat
03/15/2000CN1247089A Spirulina beverage
03/15/2000CN1247059A Non-saccharide nutritive amino acid liquid
03/14/2000USRE36617 (Substituted aralkyl) heterocyclic compounds
03/14/2000US6037488 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
03/14/2000US6037481 Process for stabilizing levogyre ascorbic acid (LAA), a stable aqueous LAA composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment
03/14/2000US6037472 For treating disease-states characterized by excessive activity of matrix metalloproteases such as rheumatoid arthritis, osteoarthritis, periodontal disease, aberrant angiogenesis, tumor invasion and metastasis
03/14/2000US6037379 Administering z-2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol
03/14/2000US6037373 Treating nervous system, cytological, hormonal, gastrointestinal and liver disorders
03/14/2000US6037362 Carbazole derivatives; deprotecting, amination; antilipemic and antidiabetic agents; b-adrenaline receptor agonists; dietetics
03/14/2000US6037324 Madcam-1 (mucosal addressin cell adhesion molecule-1); useful in the treatment of inflammatory bowel diseases and other diseases involving leukocyte infiltration of the gastrointestinal tract or other mucosal tissues
03/14/2000US6037323 Peptides and peptide analogues that mimic the structural and pharmacological properties of human apoa-i; treating disorders associated with dyslipoproteinemia, including hypercholesterolemia, cardiovascular disease, atherosclerosis,
03/14/2000US6037143 Genetically engineered protein for the treament of diabetes, osteoporosis and endometriosis
03/14/2000US6036956 Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease
03/14/2000US6036948 Polyaspartamide derivatives as adsordents for bile acids, polyaspartamide derivatives loaded with bile acids and process for their preparation and their use as pharmaceuticals
03/14/2000CA2195213C Use of droloxifene for the treatment of cardiovascular diseases
03/14/2000CA2117643C Indole derivatives
03/14/2000CA2098483C Safe adeno-associated virus 2 vector for gene therapy
03/14/2000CA2009542C Cyclic guanidines as calcium antagonists
03/14/2000CA2008263C Pyrazolopyridine compound and processes for preparation thereof
03/09/2000WO2000012741A2 Inducible expression system
03/09/2000WO2000012740A2 ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
03/09/2000WO2000012720A2 Elongase genes and uses thereof
03/09/2000WO2000012703A2 Protein transport-associated molecules
03/09/2000WO2000012682A1 Primate embryonic stem cells with compatible histocompatibility genes
03/09/2000WO2000012549A1 Protein domains in the hepatic glycogen-targetting subunit of protein phosphatase 1 and methods of making and using the same
03/09/2000WO2000012544A2 Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
03/09/2000WO2000012514A1 Novel compounds
03/09/2000WO2000012510A1 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
03/09/2000WO2000012502A1 Pyrroloquinolines for treatment of obesity
03/09/2000WO2000012493A1 Thiazoline acid derivatives
03/09/2000WO2000012481A2 Indazole derivatives with 5-ht2 receptor activity________________
03/09/2000WO2000012477A1 Hydroxamic acid derivatives as proteinase inhibitors
03/09/2000WO2000012475A1 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands
03/09/2000WO2000012467A1 N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them
03/09/2000WO2000012175A2 Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
03/09/2000WO2000012116A1 Method for administering insulinotropic peptides
03/09/2000WO2000012106A1 Gabab1aa receptor
03/09/2000WO2000012095A1 Chromium polynicotinate compositions and uses thereof
03/09/2000WO2000012085A1 Ascorbate-isoquercetin compositions
03/09/2000WO2000012084A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000WO2000012083A1 Formamides as therapeutic agents
03/09/2000WO2000012079A1 Substances having antiobese and visceral fat-reducing functions and utilization thereof
03/09/2000WO2000012074A2 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
03/09/2000WO2000012067A1 Novel pharmaceutical salt form
03/09/2000WO2000011968A1 ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
03/09/2000WO2000011952A1 Compositions and methods for treatment of mitochondrial diseases
03/09/2000WO1999062342A9 Acid and solvent modification of psyllium
03/09/2000WO1999060017A3 Human tumour-derived polypeptide hormone phosphatonin
03/09/2000WO1999058123A3 Novel fatty acid analogues for the treatment of primary and secondary restenosis
03/09/2000WO1999020260A3 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
03/09/2000CA2696878A1 Compositions and methods for treatment of mitochondrial diseases
03/09/2000CA2633074A1 Elongase genes and uses thereof
03/09/2000CA2342356A1 Chromium polynicotinate compositions and uses thereof
1 ... 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 ... 1298